Patient characteristics by time from diagnosis to first treatment
| Covariate . | Time to first treatment . | P value . | |
|---|---|---|---|
| 0-14 d, N = 300, n (%) . | 15-60 d, N = 797, n (%) . | ||
| Data set | |||
| MER | 107 (36) | 197 (25) | |
| ALLIANCE | 13 (4) | 114 (14) | |
| MCL-RCS | 180 (60) | 486 (61) | |
| Age at diagnosis, y | .70 | ||
| Median | 63 | 62 | |
| Range | 32-95 | 29-96 | |
| Sex | .85 | ||
| Female | 71 (24) | 185 (23) | |
| Male | 228 (76) | 612 (77) | |
| Race | .09 | ||
| White | 273 (94) | 697 (91) | |
| Black | 5 (2) | 35 (5) | |
| Others | 11 (4) | 29 (4) | |
| ECOG PS | <.001 | ||
| 0 | 134 (50) | 467 (63) | |
| 1 | 96 (36) | 239 (33) | |
| ≥2 | 37 (14) | 30 (4) | |
| Ann Arbor stage | .009 | ||
| 1-3 | 28 (9) | 124 (16) | |
| 4 | 267 (91) | 667 (84) | |
| LDH | <.001 | ||
| Normal | 107 (50) | 407 (64) | |
| Elevated | 106 (50) | 226 (36) | |
| BM involvement | .005 | ||
| No | 30 (11) | 135 (19) | |
| Yes | 231 (89) | 571 (81) | |
| B symptoms | .02 | ||
| No | 180 (65) | 558 (72) | |
| Yes | 97 (35) | 212 (28) | |
| MIPI | <.001 | ||
| <5.7 | 62 (31) | 277 (47) | |
| ≥5.7 <6.2 | 50 (25) | 170 (29) | |
| ≥6.2 | 88 (44) | 140 (24) | |
| Intensive induction therapy | .001 | ||
| No | 192 (64) | 425 (53) | |
| Yes | 107 (36) | 370 (47) | |
| Ki-67 percentage | .007 | ||
| ≤30% | 37 (45) | 187 (62) | |
| >30% | 45 (55) | 116 (38) | |
| Covariate . | Time to first treatment . | P value . | |
|---|---|---|---|
| 0-14 d, N = 300, n (%) . | 15-60 d, N = 797, n (%) . | ||
| Data set | |||
| MER | 107 (36) | 197 (25) | |
| ALLIANCE | 13 (4) | 114 (14) | |
| MCL-RCS | 180 (60) | 486 (61) | |
| Age at diagnosis, y | .70 | ||
| Median | 63 | 62 | |
| Range | 32-95 | 29-96 | |
| Sex | .85 | ||
| Female | 71 (24) | 185 (23) | |
| Male | 228 (76) | 612 (77) | |
| Race | .09 | ||
| White | 273 (94) | 697 (91) | |
| Black | 5 (2) | 35 (5) | |
| Others | 11 (4) | 29 (4) | |
| ECOG PS | <.001 | ||
| 0 | 134 (50) | 467 (63) | |
| 1 | 96 (36) | 239 (33) | |
| ≥2 | 37 (14) | 30 (4) | |
| Ann Arbor stage | .009 | ||
| 1-3 | 28 (9) | 124 (16) | |
| 4 | 267 (91) | 667 (84) | |
| LDH | <.001 | ||
| Normal | 107 (50) | 407 (64) | |
| Elevated | 106 (50) | 226 (36) | |
| BM involvement | .005 | ||
| No | 30 (11) | 135 (19) | |
| Yes | 231 (89) | 571 (81) | |
| B symptoms | .02 | ||
| No | 180 (65) | 558 (72) | |
| Yes | 97 (35) | 212 (28) | |
| MIPI | <.001 | ||
| <5.7 | 62 (31) | 277 (47) | |
| ≥5.7 <6.2 | 50 (25) | 170 (29) | |
| ≥6.2 | 88 (44) | 140 (24) | |
| Intensive induction therapy | .001 | ||
| No | 192 (64) | 425 (53) | |
| Yes | 107 (36) | 370 (47) | |
| Ki-67 percentage | .007 | ||
| ≤30% | 37 (45) | 187 (62) | |
| >30% | 45 (55) | 116 (38) | |
Boldface value signifies statistically significant value.